Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
+1.13M
-
Total reported value, excl. options
-
$911M
-
Value change
-
+$29M
-
Put/Call ratio
-
0.69
-
Number of buys
-
92
-
Number of sells
-
-50
-
Price
-
$30.13
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2016
183 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2016.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 62.7M outstanding shares and own 48.22% of the company stock.
Largest 10 shareholders include FMR LLC (4.8M shares), VANGUARD GROUP INC (1.74M shares), FRANKLIN RESOURCES INC (1.42M shares), JPMORGAN CHASE & CO (1.08M shares), ALLIANCEBERNSTEIN L.P. (1.05M shares), BlackRock Fund Advisors (1.04M shares), STATE STREET CORP (929K shares), EAGLE ASSET MANAGEMENT INC (874K shares), BB BIOTECH AG (851K shares), and OppenheimerFunds, Inc. (770K shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.